β-Blockers and Chronic Obstructive Pulmonary Disease: Inappropriate Avoidance?

Journal of Clinical Hypertension

Volumn 15, Issue 12, 2013, Pages 925-930

  Minor, Deborah S ^a   Meyer, Allison M ^b   Long, R C ^a   Butler, Kenneth R ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL SUCCINATE; PLACEBO; RESPIMAT; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; VERAPAMIL;

ACUTE CORONARY SYNDROME; ADRENERGIC STIMULATION; ADVERSE OUTCOME; ATHEROSCLEROSIS; BRONCHOSPASM; CARDIOPULMONARY HEMODYNAMICS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERANCE; FORCED EXPIRATORY VOLUME; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RHYTHM; HEART VENTRICLE FIBRILLATION; HOSPITALIZATION; HUMAN; HYPERTENSION; INHALER; ISCHEMIC HEART DISEASE; LUNG FUNCTION; LUNG HEMODYNAMICS; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK REDUCTION; STABLE ANGINA PECTORIS; SUDDEN CARDIAC DEATH; TACHYCARDIA; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; CARDIOVASCULAR DISEASES; HUMANS; MORBIDITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84888882726     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12204     Document Type: Review

References (49)

1. Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med. 2012;12:26-34.
2. Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173:1175-1185. doi: 10.1001/jamainternmed.2013.1016.
3. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962-969.
4. Barr RG, Ahmed FS, Carr JJ, et al. Subclinical atherosclerosis, airflow obstruction and emphysema: the MESA Lung Study. Eur Respir J. 2012;39:846-854.
5. Sin DD, Paul Man SF. A curious case of β-blockers in chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:849-850.
6. Mentz RJ, Schulte PJ, Fleg JL, et al. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION). Am Heart J. 2013;165:193-199.
7. Stefan MS, Bannuru RR, Lessard D, et al. The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction. Chest. 2012;141:1441-1448.
8. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12:48.
9. Short PM, Lipworth SI, Elder DH, et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.
10. Rutten FH, Zuithoff PA, Hak E, et al. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880-887.
11. Stefan MS, Rothenberg MB, Priva A, et al. Association between beta-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischemic heart disease, heart failure or hypertension. Thorax. 2012;67:977-984.
12. Meyer A, Butler K, Long C, et al. Beta-blockers and COPD - inappropriate avoidance? Proceedings of Mid-South Regional Pharmacy Residents Conference. 2013;66.
13. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012;22:1787-1847.
14. Lindenfeld J, Albert NM, Boehmer JP, et al. Heart Failure Society of America: 2010 Comprehensive Heart Failure Practice Guidelines. J Card Fail. 2010;16:e1-e194.
15. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the management of heart failure. J Am Coll Cardiol. 2013;June 5:S0735-S1097. doi: 10.1016/j.jacc.2013.05.019.
16. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed September 2, 2013.
17. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA Focused update incorporated into the 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e426-e579.
18. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guidelines for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;127:e362-e425.
19. Bangalore S, Steg PG, Deedwania P, et al. β-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340-1349.
20. Fox K, Garcia MAA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J. 2006;27:1341-1381.
21. Anderson JL, Halperin JL, Albert NM, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;127:1916-1926.
22. Black H, Sica D. A modern perspective on B-blocker use in hypertension: clinical trials and their influence on clinical practice. J Clin Hypertens (Greenwich). 2007;9(4 Suppl 3):10-18.
23. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489-497.
24. Mentz RJ, Wojdyla D, Fiuzat M, et al. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol. 2013;111:582-587.
25. Callaerts-Vegh Z, Evans KL, Dudekula N, et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA. 2004;101:4948-4953.
26. Nguyen LP, Omoluabi O, Parra S, et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008;38:256-262.
27. Angeloni E, Melina G, Roscitano A, et al. β-blockers improve survival of patients with chronic obstructive pulmonary disease after coronary artery bypass grafting. Ann Thorac Surg. 2013;95:525-531.
28. van Gestel YR, Hoeks SE, Sin DD, et al. Impact of cardioselective β-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008;178:695-700.
29. Farland MZ, Peters CJ, Williams JD, et al. Beta-blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother. 2013;47:651-656.
30. Ege MR, Guray U, Guray Y, et al. Acute heart failure with accompanying chronic obstructive pulmonary disease. Should we focus on beta blockers? Herz. 2012;37:796-800.
31. Camsari A, Arikan S, Avan C, et al. Metoprolol, a β-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels. 2003;18:188-192.
32. Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009;11:684-690.
33. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55:1780-1787.
34. Düngen HD, Apostolović S, Inkrot S, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011;13:670-680.
35. Lainscak M, Podbregar M, Kovacic D, et al. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive lung pulmonary disease: a randomized controlled trial. Respir Med. 2011;105(Suppl 1):S44-S49.
36. van Gestel YR, Hoeks SE, Sin DD, et al. Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD. Int J Chron Obstruct Pulmon Dis. 2009;4:177-183.
37. Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med. 2003;97:1094-1101.
38. Dransfield MT, Rowe SM, Johnson JE, et al. Use of β-blockers and the risk of death hospitalized patients with acute exacerbations of COPD. Thorax. 2008;63:301-305.
39. Qaseem A, Wilt TJ, Weinberger SE, et al; American College of Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179-191.
40. Woodruff PG. Double-edged sword? Long-acting bronchodilators in chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173:1184-1185.
41. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309-2321.
42. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
43. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:1439-1450.
44. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137:20-30.
45. Loke YK, Kwok CS, Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur Respir J. 2010;35:1003-1021.
46. Wilchesky M, Ernest P, Brophy JM, et al. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012;142:305-311.
47. Calverley PMA, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH Study results. Thorax. 2010;65:719-725.
48. Maak CA, Tabas JA, McClintock DE. Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure? J Emerg Med. 2011;40:135-145.
49. Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomized controlled trials. Thorax. 2013;68:48-56.